Last reviewed · How we verify

Handok Inc. — Portfolio Competitive Intelligence Brief

Handok Inc. pipeline: 2 marketed, 0 filed, 6 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 6 Phase 3 1 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Ciclesonide & Levocetirizine Ciclesonide & Levocetirizine marketed Inhaled corticosteroid + selective H1-receptor antagonist combination Glucocorticoid receptor (ciclesonide); H1 histamine receptor (levocetirizine) Respiratory / Allergy / Immunology
Glimepiride/metformin fixed combination Glimepiride/metformin fixed combination marketed Sulfonylurea/biguanide combination ATP-sensitive potassium channel (glimepiride); mitochondrial complex I / AMPK pathway (metformin) Diabetes
MP513 MP513 phase 3 PDE4 inhibitor PDE4 Respiratory/Pulmonology
Irbesartan/Amlodipine high Irbesartan/Amlodipine high phase 3 Angiotensin II receptor blocker / Calcium channel blocker combination AT1 receptor / L-type calcium channel Cardiovascular
Irbesartan/Amlodipine Irbesartan/Amlodipine phase 3 Angiotensin II receptor blocker / Calcium channel blocker combination AT1 receptor / L-type calcium channel Cardiovascular
Teneligliptin Placebo Oral Tablet Teneligliptin Placebo Oral Tablet phase 3 DPP-4 inhibitor DPP-4 Diabetes
Irbesartan/Amlodipine low Irbesartan/Amlodipine low phase 3 Angiotensin II receptor blocker / Calcium channel blocker combination AT1 receptor / L-type calcium channel Cardiovascular
Ketoprofen topical Ketoprofen topical phase 3 NSAID (nonsteroidal anti-inflammatory drug) COX-1, COX-2 Pain Management, Rheumatology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Novartis · 3 shared drug classes
  2. Ain Shams University · 2 shared drug classes
  3. Boryung Pharmaceutical Co., Ltd · 2 shared drug classes
  4. Dong-A ST Co., Ltd. · 2 shared drug classes
  5. GlaxoSmithKline · 2 shared drug classes
  6. Pfizer · 2 shared drug classes
  7. Amgen · 1 shared drug class
  8. Almirall, S.A. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Handok Inc.:

Cite this brief

Drug Landscape (2026). Handok Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/handok-inc. Accessed 2026-05-15.

Related